Ambulero will file an IND for our lead gene therapy product AMB-301 by late 2024.
INVESTORS AND DEVELOPMENT
Ambulero is a pioneer in the use of gene and cell therapy approaches to enhance expression of a key cell adhesion molecule (E-selectin) to treat vascular disease and non-healing wounds. We are pleased to announce our commitment to file an Investigational New Drug (IND) application for our lead product, AMB-301, by late 2024. Once achieved, this significant milestone will bring us closer to testing this gene therapy drug in the clinic.
Investment Background and National Recognition:
Initial start-up funding, management, and business support provided by Ventac Holding, LLC
Dr. Omaida Velazquez and Zhao-Jun Liu’s research supported for over a decade by grants from the NIH including funding from the prestigious Vascular Interventions/Innovations and Therapeutic Advances (VITA) program, as well as the Catalyze program of NHLBI
The research work of Dr. Velazquez and Dr. Liu supported by the Wallace H. Coulter Center for Translational Research at the University of Miami
Dr. Velazquez inducted into the American Academy of Medicine for groundbreaking research that forms the basis of Ambulero’s cell and gene therapy platform
For more information see the following links :